PTGX - Protagonist Therapeutics, Inc.
| Previous Close | 13.25 |
| Open | 13.28 |
| Bid | 13.11 x 4000 |
| Ask | 13.31 x 800 |
| Day's Range | 13.28 - 13.28 |
| 52 Week Range | 5.49 - 14.36 |
| Volume | 240 |
| Avg. Volume | 239,351 |
| Market Cap | 310.699M |
| Beta (3Y Monthly) | 1.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.96 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.17 |
- PR Newswire•2 days ago
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif., July 16, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today reported that on July 15, 2019, it issued an inducement award to Sarita Khanna, Ph.D., the Company's recently hired Vice President of Biostatistics, in accordance with the terms of Dr. Khanna's employment offer letter. The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018.
- Simply Wall St.•7 days ago
Should You Be Worried About Insider Transactions At Protagonist Therapeutics, Inc. (NASDAQ:PTGX)?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Insider Monkey•25 days ago
Here’s What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
- PR Newswire•last month
Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference
NEWARK, Calif. , June 17, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that David Liu , Ph.D., Chief Scientific Officer and Head of Research and Development, will provide ...
- PR Newswire•2 months ago
Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer
NEWARK, Calif., May 29, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced the appointment of Don Kalkofen as Chief Financial Officer. Mr. Kalkofen brings over 29 years of finance and corporate management experience to the company. "Mr. Kalkofen brings a broad range of experience with corporate management and financial oversight to Protagonist," commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer.
Motley Fool•2 months agoProtagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call Transcript
PTGX earnings call for the period ending March 31, 2019.
- PR Newswire•2 months ago
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
-- PN-943 was safe and well tolerated with gut-restricted exposure -- -- Pharmacodynamic data for PN-943 in healthy volunteers confirm higher potency observed in preclinical studies versus PTG-100 -- NEWARK, ...
- Zacks•2 months ago
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 10.77% and -37.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.•2 months ago
What You Must Know About Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Beta Value
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) then it's worth thinking about how...
- Associated Press•2 months ago
Protagonist Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the Newark, California-based company said it had a loss of 58 cents. The biopharmaceutical company posted revenue of $1.6 million in the period. Protagonist Therapeutics shares have ...
- PR Newswire•2 months ago
Protagonist Therapeutics Reports First Quarter 2019 Financial Results
-- PTG-200 collaboration agreement with Janssen Biotech expanded to include second generation oral IL-23 receptor antagonists; expanded agreement triggers $25 million milestone payment to Protagonist -- ...
- PR Newswire•2 months ago
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
NEWARK, Calif., May 8, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc. for the co-development and commercialization of PTG-200, Protagonist's first-in-class, oral peptide IL-23 receptor antagonist, for all indications including inflammatory bowel disease (IBD). The expanded agreement builds upon Protagonist's ongoing development collaboration with Janssen on PTG-200 and triggers a $25 million milestone payment to Protagonist.
- PR Newswire•2 months ago
Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019
-- Oral plenary presentation to detail properties of oral, gut-restricted alpha-4-beta-7 integrin antagonist candidate PN-943 -- NEWARK, Calif. , May 7, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. ...
- Zacks•3 months ago
Earnings Preview: Protagonist Therapeutics (PTGX) Q1 Earnings Expected to Decline
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•4 months ago
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9
NEWARK, Calif. , April 1, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present at the H.C. ...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of PTGX earnings conference call or presentation 12-Mar-19 8:30pm GMT
Q4 2018 Protagonist Therapeutics Inc Earnings Call
- Associated Press•4 months ago
Protagonist Therapeutics: 4Q Earnings Snapshot
The Newark, California-based company said it had a loss of 57 cents per share. The biopharmaceutical company posted revenue of $2.4 million in the period. For the year, the company reported that its loss ...
- PR Newswire•4 months ago
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
-- Preliminary results from the Phase 2 TRANSCEND study of the hepcidin mimetic PTG-300 for the treatment of beta thalassemia expected in the second half of 2019 -- -- U.S. Investigational New Drug (IND) ...
- PR Newswire•4 months ago
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results
-- Management to host conference call at 4:30 p.m. EDT on March 12, 2019 -- NEWARK, Calif. , March 5, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and ...
- PR Newswire•5 months ago
Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28
NEWARK, Calif. , Feb. 21, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will provide a corporate ...
- GlobeNewswire•5 months ago
Investor Expectations to Drive Momentum within Continental Resources, Protagonist Therapeutics, Mobile Mini, J & J Snack Foods, Griffon, and Nordson — Discovering Underlying Factors of Influence
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•6 months ago
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
NEWARK, Calif., Jan. 9, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that the first patient has been dosed in the Phase 2 study of PTG-300, an injectable hepcidin mimetic peptide in development for the treatment of patients with beta thalassemia, a rare disease characterized by chronic anemia and iron overload. The study is designed to evaluate the safety and preliminary efficacy of PTG-300 in patients with transfusion-dependent or non-transfusion-dependent beta thalassemia. In a completed Phase 1 study in healthy volunteers, administration of PTG-300 was well tolerated and demonstrated a dose-related and sustained reduction in serum iron levels.
